www.fdanews.com/articles/100816-rifalazil-fails-to-provide-benefit-to-patients-with-peripheral-arterial-disease
Rifalazil Fails to Provide Benefit to Patients With Peripheral Arterial Disease
November 8, 2007
ActivBiotics presented results of its PROVIDENCE-1 trial, which evaluated the effect of the antibiotic rifalazil in the treatment of intermittent claudication associated with peripheral arterial disease.
The results demonstrated that treatment for two months with rifalazil did not result in a significant improvement in walking distance, claudication onset times or other clinically relevant parameters, ActivBiotics said.
The prospective, randomized, double-blind study enrolled 297 subjects who also had high levels of antibodies to Chlamydia pneumoniae.
Steven Gilman, ActivBiotics’ chairman and CEO, said the efficacy signal in rifalazil-treated patients was only 4 percent greater than placebo.